DaVita Inc. (NYSE: DVA) is a major provider of essential kidney care services in the United States. The company specializes in offering vital dialysis treatments for patients suffering from chronic kidney failure. Operating through a large network of outpatient centers, DaVita Inc. is a key player within the competitive Medical - Outpatient and Home Healthcare industry.
Investors are keenly anticipating DaVita Inc.'s upcoming quarterly earnings report, scheduled for release on May 5th, 2026. The consensus estimate among analysts projects earnings of $2.41 per share. This forecast indicates a significant 20.5% growth in earnings per share (EPS) compared to the same quarter in the previous year, signaling strong operational performance.
Revenue is also a key focus for the upcoming report, with projections set at $3.3 billion for the quarter. This figure represents an expected increase of 2.36% year-over-year. As highlighted by Zacks Investment Research, DaVita Inc. has recently been a trending stock, attracting considerable attention from investors ahead of this crucial financial update.
Looking at valuation, DaVita Inc. has a trailing Price-to-Earnings (P/E) ratio of 17.76. This widely used metric compares the company's stock price to its earnings. The company's Price-to-Sales (P/S) ratio, which values the company based on its revenue, stands at 0.74 for the same period, offering further insight into its market valuation.
Regarding its financial health, DaVita Inc.'s Debt-to-Equity ratio is -23.12, which can indicate negative shareholder equity. Its current ratio is 1.29. This suggests DaVita Inc. possesses sufficient current assets to cover its short-term liabilities, with $1.29 available for every $1 of immediate debt, indicating reasonable liquidity.
